Apellis Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating Activities
Net income/(loss)
Adjustments to reconcile net income/(loss) to net cash used in operating activities:
Share-based compensation expense
Loss on conversion of debt
Loss on extinguishment of development liability
Loss from remeasurement of development derivative liability
Loss on disposal of fixed assets
Forfeiture of accrued interest in exchange of convertible notes
Depreciation expense
Amortization of discounts for credit facility
Amortization of discounts for convertible notes
Amortization of right of use assets
Amortization of Discounts for Credit Facility and Convertible Notes
Accretion of discount to development liability
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid assets
Other current assets
Prepaid and other current assets
Other assets
Right-of-use assets and lease liabilities
Accounts payable
Accrued expenses and other liabilities

Net cash provided by/(used in) operating activities
Investing Activities
Purchase of property and equipment
Proceeds from sale of fixed assets
Purchase of available-for-sale securities
Proceeds from maturity of available-for-sale securities
Net cash used in investing activities

Financing Activities
Proceeds from credit facility
Payment of issuance cost for credit facility
Repayment of development liability
Proceeds from settlement of capped call
Proceeds from issuance of common stock, net of issuance costs
Proceeds from issuance of common stock, pre-funded warrant offering, net of issuance costs
Payments for development derivative liability
Payments for development liability
Proceeds from exercise of stock options
Proceeds from issuance of common stock under employee share purchase plan
Payments of employee tax withholding related to equity-based compensation
Net cash provided by financing activities

Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Proceeds from income tax refunds net of income taxes paid
Convertible Notes exchanged for common stock

Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents
Restricted cash

Comments